Diasome Pharmaceuticals
- Company typePrivate
- Founded2012
- HeadquartersCleveland, United States
- Headcount1–10
- GTM typeB2B
- OfferingHardware or Manufacturing
Diasome Pharmaceuticals firmographics
Firmographics- Name
- Diasome Pharmaceuticals
- Legal name
- Diasome Pharmaceuticals, Inc.
- Website
- https://diasome.com
- Company type
- Private
- Founded year
- 2012
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Ownership category
- akta.pro rank
Diasome Pharmaceuticals industry classification
Industry- Product category
- Diabetes Therapeutics
- NAICS
- Pharmaceutical Preparation Manufacturing (325412)
- SIC
- Pharmaceutical Preparations (2834)
- akta.pro primary industry
- Pen Injectors (Insulin/GLP-1/Other Pens) (HLAHAIAC)
- akta.pro secondary industry
- Diabetes Digital Therapeutics & Dose Decision Support (Bolus Calculators) (HLAHAHAJ)
Keywords
Where Diasome Pharmaceuticals is headquartered
LocationHeadquarters
- HQ city
- Cleveland
- HQ country
- United States
- HQ region
- North America
Offices2 records
Markets served
Diasome Pharmaceuticals business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations, Supply Chain
Revenue model
- Pharmaceutical Product Sales: Once approved, Diasome will generate revenue through sales of HDV-formulated drugs, primarily HDV-Insulin Lispro for Type 1 and Type 2 diabetes. The company is also developing HDV-GLP-1 and HDV-Serotonin programs.
Go-to-market motion1 record
Distribution channels1 record
Marketing channels4 records
Diasome Pharmaceuticals product offering
Product offeringCore offering
Diasome Pharmaceuticals develops clinical-stage insulin-based and metabolic therapies using its proprietary HDV (Hepatocyte-Directed Vesicle) platform, which preferentially delivers drug actives to hepatocyte receptors in the portal-hepatic region. The company's lead product, HDV-Insulin Lispro, combines the HDV platform with insulin lispro to restore physiologic hepatic insulin exposure, while additional programs HDV-GLP-1 and HDV-Serotonin extend the platform to incretin therapy and hepatic insulin resistance respectively.
Product overview
Diasome Pharmaceuticals is advancing a new class of liver-targeted medicines through its proprietary HDV™ (Hepatocyte-Directed Vesicle) platform. The HDV platform is a first-in-class phospholipid bilayer bicelle technology that delivers therapeutic actives preferentially to hepatocytes in the portal-hepatic region, restoring liver-driven metabolic control. The company's product portfolio consists of three clinical programs: HDV-Insulin Lispro (lead program in Phase 2b for Type 1 diabetes, targeting hypoglycemia reduction), HDV-GLP-1 (preclinical/Phase 1 for Type 2 diabetes targeting the gut-liver-brain axis), and HDV-Serotonin (preclinical oral therapy for insulin resistance). Diasome's approach transforms familiar drug molecules into first-in-class, liver-directed therapies by leveraging the HDV platform's ability to bind and deliver active pharmaceutical ingredients to the liver.
Differentiator
Problem solved
Functional benefit
Products and services
- HDV (Hepatocyte-Directed Vesicle) Platform Proprietary drug delivery platform using a phospholipid bilayer bicelle with Biotin-PE surface targeting to deliver therapeutic actives preferentially to hepatocyte receptors via the SMVT transporter in the portal-hepatic region. The platform binds up to 100 proteins and peptides per disc and is compatible with insulin, GLP-1, and serotonin, supporting both injectable and oral formulations.
- HDV-Insulin Lispro Lead clinical-stage product combining the HDV platform with insulin lispro to restore physiologic liver insulin exposure in patients with Type 1 diabetes. OPTI-2 Phase 2b trial demonstrated A1C non-inferiority (<0.1% margin met at Weeks 12 and 25) with 24-36% statistically significant reductions in hypoglycemia events and zero Level 3 severe hypoglycemic events versus five with standard insulin lispro.
- HDV-GLP-1 Pipeline product applying the HDV platform to GLP-1 therapy to target the portal vein and access the gut-liver-brain axis, with the goal of improving efficacy in fat, glucose, and weight endpoints while mitigating off-target side effects. Currently in preclinical/Phase 1 stage for Type 2 diabetes.
- HDV-Serotonin First-in-class oral therapy designed to replace declining or deficient portal-hepatic serotonin levels, enabling hepatic utilization of insulin and addressing hepatic and peripheral insulin resistance in Type 2 diabetes. Currently in preclinical stage.
Quantifiable outcome
- A1C non-inferiority maintained at Weeks 12 (0.08% difference) and 25 (0.07% difference) meeting FDA's <0.1% threshold
- +4 more outcomes
Companies that use Diasome Pharmaceuticals
Customer profileNamed customers1 record
Segments3 records
Ideal customer profiles2 records
Diasome Pharmaceuticals technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature3 records
Diasome Pharmaceuticals partnerships and signals
Strategic signalPartnerships
Two partnerships are on record, tiered core and supporting.
- University of North Carolina School of MedicinecoreUNC School of Medicine researchers collaborated with Diasome on the OPTI-2 Phase 2b clinical trial. Dr. Klara Klein, MD, PhD, Assistant Professor of Medicine, served as principal investigator presenting results at ADA 86th Scientific Sessions.
- DexcomsupportingDiasome's OPTI-2 trial utilized Dexcom G7 Continuous Glucose Monitoring system throughout the 25-week treatment period for dose optimization and hypoglycemia assessment.
Scale indicators7 records
Recent moves6 records
Expansion highlights5 records
Diasome Pharmaceuticals competitors and assessment
Company assessmentEmerging players
- Zealand Pharma: Danish clinical-stage biotech developing peptide therapeutics for metabolic disease, including a dasiglucagon hypoglycemia rescue program and GLP-1/GLP-2 assets. Comparable as a small-cap European peptide-focused company overlapping with Diasome's HDV-GLP-1 and HDV-Serotonin efforts.
- DiaMedica Therapeutics: Clinical-stage biotech developing DM199 (klotho) for chronic kidney disease, diabetes, and stroke. Comparable as a small clinical-stage company advancing peptide-based therapies into metabolic disease indications overlapping with Diasome's HDV-enabled programs.
Direct peers
- Poxel SA: French clinical-stage biotech developing Imeglimin (Twymeeg) and other mitochondrial-targeted therapies for Type 2 diabetes and metabolic disease. Comparable as a small-cap European clinical-stage company targeting hepatic/mitochondrial mechanisms to address insulin resistance and glycemic control.
- vTv Therapeutics: Clinical-stage biotech focused on small-molecule therapies for metabolic disease, including Type 1 diabetes (TTP399) and renal/cardiac indications. Comparable as a small-cap, clinical-stage company pursuing differentiated mechanisms in diabetes and cardiometabolic disease.
- Adocia: French clinical-stage biotech developing reformulated insulin and GLP-1 formulations using BioChaperone delivery technology. Closest direct peer to Diasome given parallel approach of enhancing insulin pharmacology through novel formulation/delivery for diabetes and metabolic indications.
- Lexicon Pharmaceuticals: Clinical-stage biotech with a diabetes-focused pipeline (sotagliflozin / Zynquista) and broader cardiometabolic assets. Comparable as a small-cap clinical-stage company pursuing differentiated mechanisms in Type 1 and Type 2 diabetes.
- MannKind Corporation: Commercial-stage company with Afrezza (inhaled insulin) and a pipeline of endocrine/metabolic therapies. Highly comparable as a small, diabetes-focused company delivering established insulin molecules via a differentiated delivery technology to address unmet needs in mealtime glucose control.
- Oramed Pharmaceuticals: Clinical-stage biotech developing oral insulin (ORMD-0801) and an oral GLP-1 (ORMD-0901). Comparable as a small-cap, clinical-stage diabetes company reformulating established peptide drugs (insulin, GLP-1) for improved delivery — directly analogous to Diasome's HDV-Insulin and HDV-GLP-1 strategy.
Broad incumbents
- Eli Lilly and Company: One of two global leaders in insulin (Humalog, Lyumjev) and GLP-1 (Trulicity, Mounjaro, Zepbound). Broad incumbent operating across the same diabetes/obesity indications Diasome is targeting; also an investor/strategic partner in Diasome's Series C.
- Novo Nordisk: World leader in insulin (NovoLog, Fiasp) and GLP-1 (Ozempic, Wegovy). Broad incumbent across Diasome's core therapeutic categories — Type 1 and Type 2 diabetes, obesity — and a benchmark for any future commercial-scale liver-targeted insulin or GLP-1 launch.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat3 records
Key risks6 records
Key highlights7 records
Customer concentration
Diasome Pharmaceuticals social profiles
Digital presenceDiasome Pharmaceuticals financial estimates
Financial estimateRevenue estimate
Valuation estimate
Diasome Pharmaceuticals leadership team
Management profileNumber of profiles
Profiles14 records
Diasome Pharmaceuticals funding detail
Funding detailFunding overview
Funding rounds7 records
Investors6 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Diasome Pharmaceuticals M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Diasome Pharmaceuticals
What does Diasome Pharmaceuticals do?
Diasome Pharmaceuticals develops clinical-stage insulin-based and metabolic therapies using its proprietary HDV (Hepatocyte-Directed Vesicle) platform, which preferentially delivers drug actives to hepatocyte receptors in the portal-hepatic region. The company's lead product, HDV-Insulin Lispro, combines the HDV platform with insulin lispro to restore physiologic hepatic insulin exposure, while additional programs HDV-GLP-1 and HDV-Serotonin extend the platform to incretin therapy and hepatic insulin resistance respectively.
Is Diasome Pharmaceuticals a public or private company?
Diasome Pharmaceuticals is a private company. It is classified as venture growth investor backed and is currently operating.
When was Diasome Pharmaceuticals founded?
Diasome Pharmaceuticals was founded in 2012. It employs 1 to 10 people.
Where is Diasome Pharmaceuticals based?
Diasome Pharmaceuticals is headquartered in Cleveland, United States, in the North America region.
How does Diasome Pharmaceuticals make money?
One revenue line is on record: pharmaceutical Product Sales.
Who are Diasome Pharmaceuticals's main competitors?
Emerging players on record are Zealand Pharma and DiaMedica Therapeutics. Direct peers are Poxel SA, vTv Therapeutics, Adocia, Lexicon Pharmaceuticals, MannKind Corporation and Oramed Pharmaceuticals. Broad incumbents are Eli Lilly and Company and Novo Nordisk.
Does Diasome Pharmaceuticals have an API?
No public API is recorded for Diasome Pharmaceuticals.
What industry is Diasome Pharmaceuticals in?
Diasome Pharmaceuticals's product category is Diabetes Therapeutics. Its primary akta.pro industry code is HLAHAIAC, Pen Injectors (Insulin/GLP-1/Other Pens), with a secondary code of HLAHAHAJ, Diabetes Digital Therapeutics & Dose Decision Support (Bolus Calculators). Its NAICS code is 325412 and its SIC code is 2834.